The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells.

TY - JOUR

T1 - The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells.

AU - Mayr, Christian Reinhard

AU - Wagner, Andrej

AU - Loeffelberger, Magdalena

AU - Bruckner, Daniela

AU - Jakab, Martin

AU - Berr, Frieder

AU - Di Fazio, Pietro

AU - Ocker, Matthias

AU - Neureiter, Daniel

AU - Pichler, Martin

AU - Kiesslich, Tobias

N1 - Mayr1,2, Wagner1, Loeffelberger2, Bruckner3, Jakab4, Berr2, Neureiter8, Kiesslich1,2: 1 Department of Internal Medicine I, Salzburger Landeskliniken – SALK, Paracelsus Medical University, Salzburg, Austria; 2 Laboratory for Tumor Biology and Experimental Therapies, Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria; 3 Research Program for Experimental Ophthalmology and Glaucoma Research, University Clinic of Ophthalmology and Optometry, Salzburger Landeskliniken – SALK, Paracelsus Medical University, Salzburg, Austria; 4 Laboratory of Functional and Molecular Membrane Physiology, Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria; 8 Institute of Pathology, Salzburger Landeskliniken – SALK, Paracelsus Medical University, Salzburg, Austria

PY - 2016

Y1 - 2016

KW - EXTRAHEPATIC CHOLANGIOCARCINOMA CELLS

KW - STEM-CELLS

KW - HEPATOCELLULAR-CARCINOMA

KW - ANTICANCER DRUGS

KW - POOR-PROGNOSIS

KW - BREAST-CANCER

KW - IN-VITRO

KW - EXPRESSION

KW - POLYCOMB

KW - PROTEIN

U2 - 10.18632/oncotarget.6378

DO - 10.18632/oncotarget.6378

M3 - Original Article

C2 - 26623561

SN - 1949-2553

VL - 7

SP - 745

EP - 758

JO - Oncotarget

JF - Oncotarget

IS - 1

ER -